PHC Holdings buys Thermo Fisher’s anatomical pathology division
Category: #health  By Paroma Bhattacharya  Date: 2019-07-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

PHC Holdings buys Thermo Fisher’s anatomical pathology division

PHC Holdings Corporation, a global innovator in healthcare solutions, has reportedly concluded its acquisition of Thermo Fisher Scientific Inc.’s Anatomical Pathology business for approx. US$1.14 billion.

Apparently, the business of Anatomical Pathology will be operating as Epredia, a stand-alone company which will serve as a major provider of comprehensive solutions in the field of anatomical pathology that also includes instruments, consumables and microscope slides.

According to reports, a global healthcare company, PHC Holdings (PHCHD) offers value-added services and products across life sciences, healthcare IT and diabetes care. The acquisition will help PHCHD strengthen its business for diagnostics as it will expand its portfolio into oncology, further supporting the business growth.

President and CEO, PHCHD, Michael Kloss said that the company is looking forward to adding the leading global provider of anatomical pathology solutions to their group. Epredia will provide solutions and high quality products that deliver excellence of precision in cancer diagnostics.

Kloss mentioned that it is a highly successful business, showing a considerable growth and the company believes they can work together and make it more successful by being a part of the PHCHD group.

President of Epredia, James Post commented that the company is looking forward to joining PHCHD group. Despite bearing a new name, Epredia aims to fulfill the same mission, that is to enhance cancer diagnostics for patients and improve lives all over the world. The company has been powered by few key brands like the Menzel, Shandon, Richard Allan and Erie, and the customers have started to appreciate their precision and excellence, Post added.

Kloss further explained that the acquisition is essential for PHCHD group because the company sees a major potential for growth in the business and foresees opportunities for synergies with the existing business segment. This is an important step ahead for the group to continue to build a healthcare company that contributes to the health of the society and eventually improve lives. Kloss added.

Source Credit-  https://www.phchd.com/global/news/2019/0629



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Aino Health inks deal with 55BirchStreet to expand in German markets
Aino Health inks deal with 55BirchStreet to expand in German markets
By Paroma Bhattacharya

Reports confirm that Sweden’s Aino Health and 55BirchStreet, a Germany-based digital consulting firm, have recently signed a new partnership agreement. 55BitchStreet will sell implementation services and licenses...

Visa acquires Payworks for an integrated payment acceptance solution
Visa acquires Payworks for an integrated payment acceptance solution
By Paroma Bhattacharya

Visa, the financial services company recently announced acquisition of Payworks, the Munich-based makers of payment gateway software for the POS (point of sale). The company plans to integrate cloud-based solution of P...

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...